Production and Purification of Glycosaminoglycans: Methods and Challenges
Source selection, downstream processing, structural consistency and analytical quality control
Abstract
Glycosaminoglycans (GAGs) are heterogeneous, negatively charged polysaccharides whose molecular size, monosaccharide sequence, uronic acid composition and sulfation patterns influence their functions in the extracellular matrix, vascular biology and molecular recognition. Manufacturing a useful GAG material therefore requires considerably more than extracting a polymer and reporting its bulk purity. A robust process must establish the identity of the starting material, preserve relevant structural attributes, manage biological impurities and demonstrate reproducibility across lots.
This white paper examines the main production routes for hyaluronan, heparin/heparan sulfate, chondroitin sulfate and dermatan sulfate; explains extraction and fractionation techniques; and evaluates molecular-weight control, contamination risks and critical quality attributes. It distinguishes established industrial processing from promising biotechnological and chemoenzymatic alternatives. The appropriate process and release tests depend strongly on GAG class and intended use: a research-grade fraction is not automatically suitable for injectable, medical-device or pharmaceutical manufacture.
glycosaminoglycan production; GAG extraction and purification; heparin quality control; sulfated glycosaminoglycans; hyaluronic acid fermentation; molecular weight distribution; chemoenzymatic GAG synthesis
1. Introduction to GAG Production and Manufacturing
GAGs are linear polysaccharides based on repeating disaccharide units. Except for hyaluronan, commonly called hyaluronic acid (HA), mammalian GAGs typically undergo variable sulfation and are often present as chains covalently attached to proteoglycan core proteins. This chemical diversity is central to biological performance but presents a fundamental manufacturing challenge: the term “GAG” encompasses multiple product classes rather than a single manufacturing platform.
For instance, pharmaceutical heparin is a highly sulfated mixture with clinically important anticoagulant activity, whereas high-molecular-weight hyaluronan is a nonsulfated polymer valued for its rheological and hydrating properties. Dermatan sulfate and chondroitin sulfate have overlapping physicochemical behavior but different uronic acid distributions and sulfation domains. Thus, production objectives should begin with a defined target profile rather than an assumption that all charged polysaccharides can be processed interchangeably.
At a conceptual level, the manufacturing sequence comprises qualified source material, extraction or biosynthesis, clarification, targeted removal of impurities, fractionation, formulation and release testing. Each operation can alter chain length, sulfate retention or counterion composition. In many applications, the desired material is a distribution of structures, and reproducibility means controlling that distribution—not forcing every molecule to be identical.
Process yield, apparent purity and biological performance are separate quality dimensions. A high-yield process that changes the intended molecular-weight distribution or sulfate motifs may be unsuitable even when the bulk carbohydrate content appears high.
2. Major Sources of Glycosaminoglycans
2.1 Animal Tissue-Derived GAGs
Animal tissues remain major traditional sources for several sulfated GAGs. Heparin is commonly recovered from porcine intestinal mucosa, where heparin-bearing proteoglycans are present in mast-cell granules. Chondroitin sulfate can be obtained from cartilage and other connective tissues, and dermatan sulfate may be isolated from skin and related extracellular matrices. Historically, hyaluronan has also been recovered from rooster combs and other animal tissues, though microbial fermentation now supplies much of its commercial production.
Tissue-derived extraction begins with source verification and controlled collection because species, anatomical region, age, handling conditions and tissue degradation can affect polysaccharide composition. Tissue proteins, nucleic acids, lipids, salts, other GAG species and process-related residues must subsequently be separated. For heparin, supplier qualification and traceability are particularly important because structurally similar charged materials can interfere with identity testing and create serious quality risks.
The practical advantages of animal recovery include access to naturally sulfated and epimerized chain structures. Its limitations include raw-material variability, ethical and supply-chain considerations, biological contamination risk and potentially complex purification requirements. “Animal-derived” describes a source, not a guaranteed chemical composition or functional potency.
2.2 Fermentation and Biotechnological Production
Microbial fermentation is an established route for hyaluronan because certain microorganisms synthesize the polymer directly. Fermentation permits control of nutrients, aeration, agitation, pH and growth phase. Both natural HA-producing bacteria and engineered production hosts have been investigated. The broth is subsequently clarified and the polymer recovered through combinations of filtration, precipitation, membrane separation and other polishing steps.
Fermentation also introduces distinctive process constraints. As HA accumulates, broth viscosity rises, potentially impairing oxygen transfer, mixing and product recovery. Growth conditions affect the balance between polymer titer and chain size; shear and downstream exposure may decrease molecular weight. Microbial host-cell proteins, nucleic acids, cell-wall constituents and other fermentation residues require fit-for-purpose clearance and testing. Endotoxin is especially important when Gram-negative expression hosts or materials are used, but microbial contaminants should not be reduced to endotoxin alone.
Biotechnological routes to sulfated GAGs are actively studied, including engineered precursor synthesis and enzymatic post-modification. However, these pathways should not be presented as equally mature substitutes for every animal-derived sulfated GAG. Recreating heparin-like heterogeneity or a particular sulfation domain may require multiple biosynthetic enzymes, controlled donor substrates and additional fractionation.
2.3 Chemoenzymatic and Synthetic Approaches
Chemoenzymatic approaches combine defined carbohydrate substrates with glycosyltransferases, epimerases and sulfotransferases to assemble chains and introduce desired modifications. Recombinant enzymes and activated sugar donors can improve positional control relative to bulk tissue extraction. Such methods are particularly useful for preparing structurally informative heparan sulfate/heparin oligosaccharides and reference materials for binding studies.
Conventional chemical synthesis can achieve precise control over short oligosaccharides, but protection/deprotection cycles, stereochemistry and site-selective sulfation complicate extension to longer highly modified products. Chemoenzymatic synthesis reduces some of those challenges without eliminating them. Enzyme selectivity, substrate conversion, donor costs, product separation and scalable verification of sequence-specific features remain major development considerations. These methods are especially promising where a well-defined motif matters more than a broad natural polymer distribution.
| Source or route | Representative GAGs | Advantages | Main manufacturing limitations |
|---|---|---|---|
| Animal tissue extraction | Heparin, chondroitin sulfate, dermatan sulfate | Access to naturally modified sulfated chains | Source variability, traceability, co-extracted biomolecules, contamination risk |
| Microbial fermentation | Hyaluronan; certain engineered GAG-related intermediates | Controlled bioprocess, non-animal HA supply, process optimization | High viscosity, molecular-weight dispersity, host-related contaminants |
| Chemoenzymatic production | Defined heparan sulfate/heparin fragments and other tailored GAG structures | Targeted sulfation and structural design | Enzyme/donor requirements, complex analytics, scale-up cost |
| Multistep chemical synthesis | Short, structurally defined oligosaccharides | Fine control of designed structures | Labor-intensive chemistry and reduced practicality for highly complex long chains |
Figure 1. Three production routes for GAG materials converge on source-appropriate purification and orthogonal quality characterization. Conceptual workflow; not a validated batch process.
3. Extraction and Initial Processing
Primary processing is chosen according to the biological matrix and the stability of the target polymer. In a tissue workflow, mechanical disruption and controlled protein breakdown can release GAG-containing components from extracellular matrices or proteoglycans. Removal of insoluble tissue, lipids and large protein fragments helps reduce the load on downstream separation. The specific sequence and reagent conditions depend on tissue composition, GAG identity and the impurity profile; they cannot be generalized into a universal manufacturing protocol.
Proteolytic treatment can improve recovery from protein-rich starting materials but requires clearance of residual proteases and peptide fragments. Solvent-assisted or salt-dependent operations may facilitate isolation, yet aggressive pH, temperature or oxidative exposure can damage chains or modify sulfation. A process must therefore balance complete liberation of target material against unwanted depolymerization and loss of functional structural motifs.
For fermentation broths, primary recovery normally focuses on cell separation, broth clarification and managing viscosity. High-molecular-weight HA may complicate membrane transport or precipitate handling, while microbial nucleic acids and proteins can remain associated with the product. Processing order should be evaluated because removing biological solids before a concentration step can reduce membrane fouling and improve purification consistency.
Mass-balance checkpoints are informative at this stage. Reporting only final dry mass may obscure losses of target GAG and carryover of salts or non-GAG solids. Analysts can track total carbohydrate, identity-specific content, molecular-weight distributions and impurity classes across unit operations. The analytical recovery model should use the same calibrated basis at each sampling point.
4. Purification and Fractionation Strategies
GAG purification commonly exploits differences in net negative charge, chain length, solubility and interaction with a separation medium. The resulting chromatographic or membrane fraction is defined operationally, and selection of a technique depends on the resolution required. A strongly anionic GAG is not necessarily a single chemical species; similar bulk charge can conceal substantial structural differences.
4.1 Charge-Based Separation
Anion-exchange chromatography retains negatively charged GAGs on positively charged media and elutes them under altered ionic conditions. It is useful for separating broad charge classes and removing some contaminants. Sulfate density and polymer length both affect retention, so a single chromatographic peak does not establish a unique sulfation sequence. Weak and strong anion exchangers can offer different selectivity, and performance should be verified against representative impurity and product profiles.
4.2 Size-Based Separation
Size-exclusion chromatography can be useful for analytical profiling and fractionating certain GAG size ranges, particularly oligomers. Ultrafiltration and diafiltration are attractive for concentration, solvent exchange and removing smaller solutes, provided the membrane and operating conditions suit the polymer. Membrane molecular-weight cutoffs do not provide a precise molecular-weight boundary for flexible, charged polysaccharides; adsorption and broad distributions can complicate recovery.
4.3 Precipitation and Polishing
Selective precipitation may enrich polymer relative to lower-molecular-weight contaminants, especially in early recovery, but can also co-precipitate other polyanions or proteins. Polishing operations may address remaining salts, protein residues, solvents, microbial components and charge-distribution outliers. The process should be designed around measured impurity removal, not simply the number of purification stages used.
| Technique | Separation principle | Typical purpose | Important caveat |
|---|---|---|---|
| Anion-exchange chromatography | Charge and ionic interactions | Broad sulfation/charge fractionation | Same net charge does not imply same sequence |
| Size-exclusion chromatography | Hydrodynamic size | Analytical sizing or oligomer fractionation | Calibration depends on GAG conformation |
| Ultrafiltration/diafiltration | Membrane retention and permeation | Concentration, buffer exchange and small-solute clearance | Broad retention behavior and membrane fouling |
| Selective precipitation | Solubility differences | Bulk polymer recovery | Possible co-precipitation and variable recovery |
| HILIC or ion-pair LC (analytical) | Combined polarity/partition mechanisms | Oligosaccharide and disaccharide profiling | Usually an analytical rather than bulk-production tool |
5. Molecular Weight and Composition Control
Molecular weight influences viscosity, diffusion, protein-binding avidity and, for particular GAGs, functional bioactivity. A meaningful specification generally includes the distribution rather than one average value. Number-average molecular weight (Mn), weight-average molecular weight (Mw), dispersity (Mw/Mn) and proportions of selected size fractions may each provide different information. Analytical method, calibration standards and sample conditions should accompany reported molecular-weight data.
For HA, fermentation conditions and downstream shear affect chain growth and degradation. For animal-derived sulfated GAGs, source selection, extraction severity and fractionation influence the recovered size profile. Enzymatic cleavage can create defined oligosaccharides, but cleavage specificity and reaction extent must be characterized. Chemical depolymerization may change chain termini or other structural attributes and cannot be assumed equivalent to a size-only adjustment.
Composition control is equally important for sulfated GAGs. Disaccharide profiling after suitable enzymatic depolymerization can characterize commonly observed sulfation motifs, while nuclear magnetic resonance (NMR), mass spectrometry and complementary techniques contribute structural information. However, disaccharide frequencies do not fully recover the order of motifs along an intact chain. This distinction matters when a specific sequence domain drives a protein interaction.
For mixtures such as sulodexide GAG fractions, the proportion of fast-moving heparin-related material and dermatan sulfate is another relevant compositional attribute. A nominal bulk ratio alone is insufficient to establish consistency in molecular size, specific sulfation features or cofactor-related bioactivity.
6. Impurities, Contamination and Safety Considerations
Potential contaminants depend on origin. Animal extracts may contain residual proteins, nucleic acids, other polysaccharides, viruses or other adventitious agents, and species-mismatched raw materials. Fermentation-based materials may carry residual host-cell components, nucleic acids, medium-related substances or microbial impurities. Processing chemicals, solvents, salts and filtration-related extractables may also require evaluation. Risk assessment must follow the intended application, with more stringent requirements for drug or invasive-device uses than for many research-only assays.
Heparin illustrates why identity testing must be more discriminating than bulk charge or generic carbohydrate assays. The 2008 heparin contamination crisis involved oversulfated chondroitin sulfate (OSCS), a structurally different but strongly anionic adulterant. Subsequent oversight emphasized source controls and improved analytical detection. This historical example should not be mistaken for ordinary residual chondroitin sulfate contamination: deliberate oversulfation changes the material's analytical behavior and clinical risk profile.
Recommended analytical strategies are orthogonal: they combine methods that interrogate different material attributes. NMR may detect certain unexpected structural signatures; chromatographic profiling can investigate size or charge anomalies; mass spectrometry and disaccharide analysis assess composition; and suitable biological assays establish relevant potency or functional consistency. No single test proves the absence of every potential contaminant.
| Impurity class | Examples or sources | Assessment strategy |
|---|---|---|
| Biological residues | Host-cell or tissue proteins, nucleic acids | Validated protein/DNA methods and process clearance evidence |
| Microbial contamination | Bioburden, endotoxin, other microbial substances | Application-specific microbiological assays and controls |
| Related polysaccharides | Co-extracted GAGs, atypical high-charge adulterants | Identity and compositional methods, NMR and appropriate chromatography |
| Process-derived residues | Solvents, salts, detergents or reagents | Relevant chemical residual testing and validated clearance |
| Structural degradation | Excessive chain scission or altered sulfate profile | Size distribution, sulfation mapping and functional testing |
This discussion is a scientific overview, not a validated GMP protocol. Manufacturing controls, pharmacopoeial methods, impurity acceptance limits and release specifications must be established for the particular material, jurisdiction and intended use.
7. Batch-to-Batch Consistency and Quality Assessment
Batch consistency begins upstream. A source-qualification program should document tissue species and origin, supplier traceability or fermentation strain identity, incoming material acceptance, and process parameters linked to critical quality attributes. Changes in supplier, bioreactor conditions or purification media can affect GAG composition even if final bulk yield appears unchanged.
An effective testing strategy separates identity, purity, physical properties and biological activity. Identity should demonstrate the correct GAG class, not merely an expected negative charge. Molecular-weight distribution, sulfation and disaccharide composition may be critical for the intended application. For an HA hydrogel experiment, rheological properties may be central; for heparin-like studies, relevant functional anticoagulant assays may be needed in addition to chemical profiling.
Orthogonal assessments also strengthen troubleshooting. If a batch shows unusual apparent binding in a cell assay, independent endotoxin analysis can distinguish a potential inflammatory artifact from GAG-specific effects. If two lots have similar disaccharide composition but different binding affinities, oligomer size, motif distribution or assay conditions may explain the difference. Each analysis informs a different level of confidence.
| Quality attribute | Example technique | Question addressed |
|---|---|---|
| GAG identity | NMR, selective enzymatic digestion, compositional profiling | Is the intended polysaccharide class present? |
| Size distribution | SEC with suitable detectors, calibrated electrophoretic methods | Is the chain-length profile reproducible? |
| Sulfation composition | Disaccharide LC-MS, NMR, other validated methods | Are measured motifs and charge features comparable? |
| General purity | Protein/DNA assays and targeted residual testing | Have source and process impurities been controlled? |
| Microbiological quality | Bioburden and endotoxin tests where applicable | Could contaminants distort use or increase risk? |
| Functional activity | Fit-for-purpose anticoagulant, binding or rheological assays | Does the material perform as intended? |
Figure 2. A multi-attribute approach to GAG lot comparability. An acceptable analytical profile must be defined by the intended use and a justified specification.
8. Current Manufacturing Challenges and Emerging Technologies
Reducing animal-source dependence. Industrial fermentation provides a successful model for HA, and metabolic engineering is expanding the range of available carbohydrate intermediates. But producing complex sulfated GAGs with natural-like domain organization remains significantly more challenging than secreting a nonsulfated HA chain.
Making structural variability measurable. Average sulfation and molecular weight provide useful process metrics but do not fully describe sequence domains. Advances in high-resolution LC-MS, enzymatic sequencing, NMR and chemoinformatics may make compositional comparisons more sensitive and mechanistically meaningful. Interpretation still relies on appropriate standards and validated workflows.
Balancing process economy and selectivity. Resin-based polishing, membrane separation and other recovery steps must be selected with yield, impurity clearance and chain preservation in mind. Continuous production strategies, improved bioreactors and automated process monitoring are under investigation, especially for HA fermentation. Any process intensification approach still needs evidence of comparable molecular structure and relevant activity.
Designing fit-for-purpose materials. Chemoenzymatic methods may supply selectively sulfated GAG oligosaccharides for mechanistic studies, while well-characterized broader mixtures may remain useful when native heterogeneity itself is biologically relevant. Both routes benefit from reference standards, transparent batch documentation and study-specific analytical specifications.
Future manufacturing improvements will likely come from integrating biosynthetic pathway engineering, process analytical technology and deeper structural analytics. However, the optimal technical path will differ for GAG-based research materials versus pharmaceutical active ingredients. High analytical resolution and transparent quality documentation are central to both.
GAG production is best viewed as a combination of sourcing, controlled biosynthesis or extraction, selective purification and structure-sensitive quality assessment. Matching the process to the required GAG class and intended function is more useful than pursuing high polymer purity as a stand-alone goal.
References
- Serra M, Casas A, Toubarro D, Barros AN, Teixeira JA. Microbial hyaluronic acid production: a review. Molecules. 2023;28(5):2084. doi:10.3390/molecules28052084.
- Liu J, Linhardt RJ. Chemoenzymatic synthesis of heparan sulfate and heparin. Nat Prod Rep. 2014;31(12):1676–1685. doi:10.1039/C4NP00076E.
- Marwan-Abdelbaset E, Samy-Kamal M, Tan D, Lu X. Microbial production of hyaluronic acid: The current advances, engineering strategies and trends. J Biotechnol. 2025;403:52–72. doi:10.1016/j.jbiotec.2025.03.015.
- Borujeni NE, Armagan HS, Demirci A. Microbial hyaluronic acid production by integrating molecular structure, biological function, purification, and application. Int J Biol Macromol. 2026;339(Pt 2):149963. doi:10.1016/j.ijbiomac.2025.149963.
- Zappe A, et al. State-of-the-art glycosaminoglycan characterization. Mass Spectrom Rev. 2022. doi:10.1002/mas.21737.
- U.S. Food and Drug Administration. Heparin for Drug and Medical Device Use: Monitoring Crude Heparin for Quality. Guidance for Industry. 2013. FDA guidance.
- Liu L, Liu Y, Li J, Du G, Chen J. Microbial production of hyaluronic acid: current state, challenges, and perspectives. Microb Cell Fact. 2011;10:99. doi:10.1186/1475-2859-10-99.